Since 1923, we have been focused on innovation and leadership in diabetes care. Today we have a broad portfolio of medicines.
Since the launch of our first pen needle in 1985, we have been committed to enhancing injection experience by putting technology in patient hands.
Access information on our products for rare bleeding disorders, growth hormone-related disorders, and women's health.
Chronic Weight Management
Find information on our treatment for chronic weight management in adults who are overweight with one weight-related comorbidity or obesity.
The following link used in conjunction with the FDA-approved product labeling may be used to determine U.S. patents associated with the corresponding U.S. marketed product.
Making a positive difference in people’s lives is at the heart of everything Novo Nordisk does – through groundbreaking science, sustained focus on the environment, and patient-centered care.
Our Media Relations team is ready to help you get all the information you need about Novo Nordisk.
Novo Nordisk today announced that the company will share data from 39 abstracts discussing a breadth of new clinical, real-world and patient perspectives data across its portfolio of pipeline and...
The American Heart Association (AHA) and the American Diabetes Association (ADA) today announced the start of a new multi-year collaborative initiative supported by founding sponsors...
A new head-to-head pharmacokinetic study showed that adults with hemophilia B who received a single dose (50 IU/kg) of Rebinyn® [Coagulation Factor IX (Recombinant), GlycoPEGylated] achieved high...
Novo Nordisk today announced an increased commitment to stem cell-based therapies and an expansion of the focus on type 1 diabetes...
Visit the download center to download Novo Nordisk video and more
Sign up to receive our new alerts